Navigation Links
Genesis Biopharma Issues Letter To Shareholders
Date:5/21/2012

LOS ANGELES, May 21, 2012 /PRNewswire/ -- Genesis Biopharma, Inc. (OTC/BB: GNBP), a biotechnology company developing targeted cancer immunotherapies, announces the posting of the following Letter to Shareholders to the Investors section of the Company's website at www.genesis-biopharma.com.  In addition, on May 15, 2012, the Company filed with the U.S. Securities and Exchange Commission its Quarterly Report for the three months ended March 31, 2012 on Form 10-Q.  The Form 10-Q includes unaudited interim consolidated financial statements containing the information highlighted below, as well as additional information regarding the Company.  The Form 10-Q is available at www.sec.gov or www.genesis-biopharma.com

Dear Shareholders:

The past months have been a productive and exciting time for Genesis Biopharma as we worked diligently to advance the clinical development of our targeted cancer immunotherapy, a ready-to-infuse autologous cell therapy ("ACT") utilizing tumor infiltrating lymphocytes ("TILs") for the treatment of patients with Stage IV metastatic melanoma.  ACT is based on a physician-sponsored investigational therapy currently available at the National Cancer Institute ("NCI"), MD Anderson Cancer Center and the H. Lee Moffitt Cancer & Research Institute for this same indication. 

During the fourth quarter of 2011, we were pleased to announce our Patent License Agreement with the National Institutes of Health ("NIH"), under which Genesis Biopharma was granted a non-exclusive worldwide license to 43 patents and patent applications.  These include nine U.S. issued patents, 13 U.S. patent applications, and 21 foreign corresponding patents and patent applications relating to adoptive cell therapy using autologous TILs for the treatment of certain cancers. 

W
'/>"/>

SOURCE Genesis Biopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Genesis Biopharma Announces Proposed Public Offering of Common Stock and Warrants
2. ValGenesis Suite 2.5 Certified by SAP as Powered by SAP NetWeaver®
3. Scott Brooks Joins Regenesis Biomedical as Chief Operating Officer
4. ThermoGenesis Announces Approval of AXP® by India Ministry of Health
5. ThermoGenesis Announces Acceptance of AXP® Submission by Regulatory Body in China
6. Genesis Biosciences Announces New Hire and Promotions on Operational and Scientific Staff
7. ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal 2011 on September 12, 2011
8. Genesis Biopharma Signs Cooperative Research and Development Agreement With the National Cancer Institute to Develop Cancer Immunotherapies
9. Genesis Biopharma Names Former Member of the Joint Chiefs of Staff General Merrill McPeak to Board of Directors
10. Genesis Biopharma Names David Voyticky to Board of Directors
11. Genesis Biopharma Director William H. Andrews, Ph.D., Profiled in Popular Science Feature Story
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... DC (PRWEB) January 14, 2014 Carahsoft ... for Thursday, January 23, 2014 at 2pm EST (11am ... Knowledge.” The topic focuses on how technology can turn ... critical decisions for government agencies. The online webinar will ...
(Date:1/14/2014)... pet owners drew up their lists of New Year,s resolutions for ... of my furry companion." Nowadays there are pet salons, dog and ... take the little canine or feline darlings along wherever mommy or ... pricey toys at the pet store. But anyone who has ever ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014  Organovo ... institutes from the National Institutes of Health (NIH) to ... more effective treatments to patients on a faster timeline. ... Translational Sciences (NCATS) and the National Eye Institute (NEI) ...
(Date:1/14/2014)... 14, 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a ... innovative therapies addressing major unmet medical needs using ... Notice of Allowance from the United States Patent ... compounds (sd-rxRNA®), for the treatment of fibrosis. The ...
Breaking Biology Technology:Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... subsidiary in Philadelphia Area -, PHILADELPHIA, Feb. ... cellular imaging, announced today the appointment of Chris ... subsidiary of Paris-based Mauna,Kea Technologies and develops and ... improves patient care by eliminating the,need for unnecessary ...
... Prescription Rates, According ... to a New Report from Decision Resources, WALTHAM, ... leading research and advisory firms focusing on pharmaceutical and,healthcare ... ustekinumab will become the clinical gold standard,for psoriasis by ...
... the world,s leading,online bioscience job board and life ... pharmaceutical job candidates at its Biotech,Bay Career Fair ... The BioSpace Career Fair drew a steady ... career candidates from,around the Northern California region. For ...
Cached Biology Technology:Chris Tihansky Appointed President of In Vivo Cellular Imaging Leader Cellvizio Inc. 2Centocor/Janssen-Cilag's Ustekinumab Will Become the Gold Standard for Psoriasis By 2011 2BioSpace Career Fair in San Francisco Welcomes Over 1,000 Bioscience Professionals 2
(Date:4/22/2014)... London PETA International Science Consortium Ltd.,s nanotechnology expert ... strategy for nanomaterial hazard assessment" at the 7th ... 2014, in Antalya, Turkey. , Dr. Monita Sharma ... from the US National Academy of Sciences, " Toxicity ... Strategy ," which recommends use of non-animal methods involving ...
(Date:4/22/2014)... nanotechnology researchers at the University of Kentucky has discovered ... using RNA. , The research, led by Peixuan ... Nanobiotechnology at the UK College of Pharmacy and Markey ... as a Boiling-Resistant Anionic Polymer Material To Build Robust ... F. Khisamutdinov and Daniel L. Jasinski. , The article, ...
(Date:4/22/2014)... and precipitation on the global distribution of plant and ... the UV-B radiation, is often neglected. The landscape ecologists ... Universities in Olomouc (Czechia), Halle and Lneburg have processed ... such a way that they can be used to ... The basic input data were provided by a NASA ...
Breaking Biology News(10 mins):RNA shows potential as boiling-resistant anionic polymer material for nanoarchitectures 2UV-radiation data to help ecological research 2
... in Uganda who self-paid for their antiretroviral medications experienced ... or supply logistical disruptions. These treatment interruptions led ... patients. , These findings by a team led by ... Kampala, and UCSF are reported in the April 22, ...
... pediatric specialists at Baylor College of Medicine have discovered a ... that allows drugs to enter cancer cells. , The research ... and Biomolecular Chemistry. , All living cells defend themselves ... form a protective cocoon around the cell's inner machinery and ...
... cells to turnover their contents, something that they do ... and radiation, but it is not known if this ... survive the anti-cancer therapy. However, in a study using ... the University of Pennsylvania have now shown that autophagy ...
Cached Biology News:Resistance to anti-HIV drugs in Uganda developed due to drug supply problems 2Buckyballs used as 'passkey' into cancer cells 2
Recombinant Viral CCI/Fc Chimera, CF...
... DeStreak Reagent, 1 ml. ... 2-D gels by preventing streaking.Eliminates ... oxidation of proteins.Stabilizes proteins throughout ... simplified, well-resolved protein patterns.Ideal for ...
LIVE/DEAD® Cell-Mediated Cytotoxicity Kit *for animal cells* *2000 assays*...
SlowFade Antifade Kit with DAPI...
Biology Products: